Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 19, 2026 | -$0.15 | -$0.27 | Miss |
| May 14, 2026 | -$0.04 | -$0.22 | Miss |
| Mar 19, 2026 | -$0.20 | -$0.24 | Miss |
| Nov 13, 2025 | -$0.20 | -$0.02 | Beat |
| Aug 14, 2025 | -$0.20 | -$0.36 | Miss |
| May 15, 2025 | -$0.20 | -$0.56 | Miss |